Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 52

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 52
---
 for the fiscal year ended December 31, 2024.

The Compensation Committee

Daniel Tassé, Chair

Alexandra Glucksmann, Ph.D.

A.N. “Jerry” Karabelas, Ph.D.

<div align='center'>37</div>

Summary Compensation Table The following table provides information concerning the compensation earned by our NEOs during the years ended December 31, 2024, 2023 and 2022:

| Name and Principal Position |     | Year |     |  Salary 
     ($) |     |     Stock 
 Awards(1) 
       ($) |     |    Option 
 Awards(1) 
       ($) |     |      Non-Equity 
  Incentive Plan 
 Compensation(2) 
             ($) |     |       All Other 
 Compensation(3) 
             ($) |     |     Total 
       ($) |
| Curran Simpson(4)           |     | 2024 |     | 571,723 |     | 1,330,383 |     | 2,572,911 |     |         289,689 |     |          19,838 |     | 4,784,543 |
| President and CEO           |     | 2023 |     | 512,928 |     | 1,511,776 |     |   739,622 |     |         166,701 |     |          18,975 |     | 2,950,002 |
|                             |     | 2022 |     | 474,933 |     |   367,117 |     | 1,052,652 |     |         185,224 |     |          17,538 |     | 2,097,463 |
| Mitchell Chan(5)            |     | 2024 |     | 141,346 |     |   749,991 |     | 2,249,992 |     |          56,921 |     |           7,044 |     | 3,205,294 |
| EVP, Chief Financial        |     |      |     |         |     |           |     |           |     |                 |     |                 |     |           |
| Officer                     |     |      |     |         |     |           |     |           |     |                 |     |                 |     |           |
| Stephen Pakola, M.D.        |     | 2024 |     |